Literature DB >> 8566602

Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells.

M Pinzani1, S Milani, R De Franco, C Grappone, A Caligiuri, A Gentilini, C Tosti-Guerra, M Maggi, P Failli, C Ruocco, P Gentilini.   

Abstract

BACKGROUND & AIMS: Endothelin (ET) 1 could be involved in the regulation of hepatic microcirculation and in the development of portal hypertension. The expression and distribution of ET-1 in normal and cirrhotic liver tissue and its effects on hepatic stellate cells (HSCs), liver-specific pericytes, were investigated.
METHODS: ET-1 expression in liver tissue was analyzed using in situ hybridization and immunohistochemistry. Secretion of ET-1 by HSC was evaluated by radioimmunoassay. Changes in intracellular Ca2+ concentration and cell contraction were studied using digital video imaging. Specific binding of ET-1 was evaluated using self- and cross-displacement curves.
RESULTS: ET-1 expression was markedly enhanced in cirrhotic liver tissue, where activated HSCs were shown to be major sites of ET-1 synthesis, as confirmed by studies performed on cultured human HSC. ET-1 exerted several biological actions on HSC, including mitogenicity, activation of mitogen-activated protein kinase, and a rapid increase in intracellular Ca2+ coupled with reversible cell contraction. All these effects appeared to be mediated by ETA receptors. Finally, the relative prevalence of ETA and ETB binding sites changed with the progressive phenotypical modulation of HSC.
CONCLUSIONS: ET-1 may act as a paracrine and autocrine factor for activated HSC and contribute to the increased resistance to portal flow in cirrhotic liver.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8566602     DOI: 10.1053/gast.1996.v110.pm8566602

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  77 in total

Review 1.  Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension.

Authors:  H Reynaert; M G Thompson; T Thomas; A Geerts
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

Review 2.  Hepatopulmonary syndrome.

Authors:  M B Fallon; G A Abrams
Journal:  Curr Gastroenterol Rep       Date:  2000-02

3.  Effects of orthotopic liver transplantation on vasoactive systems and renal function in patients with advanced liver cirrhosis.

Authors:  Concepcíon Cassinello; Enrique Moreno; Adolfo Gozalo; Blanca Ortuño; Beatriz Cuenca; José Antonio Solís-Herruzo
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

4.  Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis.

Authors:  Y Yang; E M Nemoto; S A K Harvey; V M Subbotin; C R Gandhi
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

5.  Preproendothelin-1 expression is negatively regulated by IFNγ during hepatic stellate cell activation.

Authors:  Tianxia Li; Zengdun Shi; Don C Rockey
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-02-02       Impact factor: 4.052

6.  NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension.

Authors:  S Fiorucci; E Antonelli; O Morelli; A Mencarelli; A Casini; T Mello; B Palazzetti; D Tallet; P del Soldato; A Morelli
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

7.  Prostaglandin E2 induces contraction of liver myofibroblasts by activating EP3 and FP prostanoid receptors.

Authors:  S Ayabe; T Murata; T Maruyama; M Hori; H Ozaki
Journal:  Br J Pharmacol       Date:  2009-02-23       Impact factor: 8.739

8.  An endothelin A receptor antagonist induces dilatation of sinusoidal endothelial fenestrae: implications for endothelin-1 in hepatic microcirculation.

Authors:  Norihito Watanabe; Shinji Takashimizu; Yasuhiro Nishizaki; Seiichiro Kojima; Tatehiro Kagawa; Shohei Matsuzaki
Journal:  J Gastroenterol       Date:  2007-09-25       Impact factor: 7.527

9.  Antifibrotic effects of ambrisentan, an endothelin-A receptor antagonist, in a non-alcoholic steatohepatitis mouse model.

Authors:  Toshiaki Okamoto; Masahiko Koda; Kennichi Miyoshi; Takumi Onoyama; Manabu Kishina; Tomomitsu Matono; Takaaki Sugihara; Keiko Hosho; Junichi Okano; Hajime Isomoto; Yoshikazu Murawaki
Journal:  World J Hepatol       Date:  2016-08-08

10.  Endothelin inhibits cholangiocarcinoma growth by a decrease in the vascular endothelial growth factor expression.

Authors:  Giammarco Fava; Sharon Demorrow; Eugenio Gaudio; Antonio Franchitto; Paolo Onori; Guido Carpino; Shannon Glaser; Heather Francis; Monique Coufal; Luca Marucci; Domenico Alvaro; Marco Marzioni; Trenton Horst; Romina Mancinelli; Antonio Benedetti; Gianfranco Alpini
Journal:  Liver Int       Date:  2009-03-09       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.